The chart below summarizes recommendations regarding screening for sexually transmitted infections from three organizations: the American Congress of Obstetricians and Gynecologists (ACOG), the U.S. Preventive Services Task Force (USPSTF), and the Centers for Disease Control and Prevention (CDC).
[tabby title=”Chlamydia”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Annual Screening for sexually active females age 25 and younger
- Screening for women over age 25 with risk factors (e.g., new/multiple partners)
U.S. Preventive Services Task Force (USPSTF)
- Screening for all sexually active non-pregnant females age 24 and younger. The optimal interval for screening this population is not known; noted that CDC recommends annually.
- Screening for all pregnant women ages 24 and younger, and pregnant women over 24 who have risk factors (e.g., new sexual partner, unprotected sex, STI history).
- Insufficient evidence to recommend screening in males.
Centers for Disease Control and Prevention (CDC)
- All pregnant women
- Annual testing for all sexually active women under age 26
- Women 26 and older women with risk factors (new or multiple sex partners)
- No routine testing for men, but consider screening men in high-prevalence settings (correctional facilities, STD clinics)
[tabby title=”Gonorrhea”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Annual Screening for sexually active females age 25 and younger
- Screening for women over age 25 with risk factors (e.g., new/multiple partners)
U.S. Preventive Services Task Force (USPSTF)
- All sexually active females, including those who are pregnant, if they have risk factors (similar to those with chlamydia)
- Insufficient evidence to recommend routine screening for males
Centers for Disease Control and Prevention (CDC)
- Pregnant women with risk factors (see chlamydia)
- Wide screening is not recommended
- argeted screening of women under age 26 at increased risk is prime component of gonorrhea control in the U.S.
- Screen sexually active MSM annually for: urethral gonorrhea if insertive sex; rectal gonorrhea if receptive anal sex, pharyngeal gonorrhea if performed oral sex
[tabby title=”Syphilis”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Adolescents should be tested if risk factors are present
U.S. Preventive Services Task Force (USPSTF)
- Persons at increased risk (MSM, commercial sex work, unprotected sex, those in correctional facilities)
- All pregnant women
- The Task Force makes no recommendation on routine screening of men and non-pregnant women not at increased risk for infection
Centers for Disease Control and Prevention (CDC)
- All pregnant women
- All sexually active MSM
[tabby title=”Genital Herpes”]
American Congress of Obstetricians and Gynecologists (ACOG)
- No specific population guidelines
U.S. Preventive Services Task Force (USPSTF)
- The Task Force does not recommend routine screening in asymptomatic adolescents and adults, including pregnant women.
Centers for Disease Control and Prevention (CDC)
- Evidence does not support screening pregnant women for HSV-2
[tabby title=”Hepatitis B”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Pregnant women
- Infants born to infected mothers
- Sex partners of (and those living with) HBV+ persons
- HIV+ persons
- Injecting drug users
- MSM
- Healthcare workers with occupational exposure
- Those treated with immunosuppressive drugs
U.S. Preventive Services Task Force (USPSTF)
- Pregnant women at their first prenatal visit
- The Task Force does not recommend routine screening for the asymptomatic general population
Centers for Disease Control and Prevention (CDC)
- Routine screening of all pregnant women
- Sexually-active MSM
- Pre-vaccination screening an option for household, sexual, and needle-sharing contacts of HBV+ persons (to save costs of needless immunization)
[tabby title=”Hepatitis C”]
American Congress of Obstetricians and Gynecologists (ACOG)
- HIV+
- Injecting drug users
- Those receiving clotting factors before 1987
- Dialysis patients
- Abnormal liver enzyme tests
- Blood transfusion before 1992
- Healthcare workers with occupational exposure
U.S. Preventive Services Task Force (USPSTF)
- The Task Force does not recommend routine screening for the asymptomatic general population.
- Insufficient evidence to recommend for or against routine screening for those with risk factors
Centers for Disease Control and Prevention (CDC)
- All persons with HIV should be tested
- Those with a history of injection drug use
- Routine testing of MSM should be considered.
[tabby title=”HIV”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Women and men ages 19-64
- Pregnant women and those in other age groups who have risk factors
U.S. Preventive Services Task Force (USPSTF)
- All adolescents and adults at increased risk for infection (MSM, unprotected sex and multiple partners, commercial sex workers, injection drug users, blood transfusion between 1978 and 1985).
- The Task Force makes no recommendation for screening those without risk factors.
Centers for Disease Control and Prevention (CDC)
- HIV screening for patients ages 13-64 in all healthcare settings
[tabby title=”Pap Test”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Begin at age 21
- Under 30, Pap every two years
- 30 and over, Pap every three years with interval extended to three years following three consecutive, normal tests
U.S. Preventive Services Task Force (USPSTF)
- Cytology in women ages 21-65 every three years
- Centers for Disease Control and Prevention (CDC)
- Summarized cervical cancer screening guidelines published by ACS, ACOG, and ASCCP
[tabby title=”HPV Test”]
American Congress of Obstetricians and Gynecologists (ACOG)
- Women 30 and older may be tested with cytology alone or HPV/Pap co-testing
U.S. Preventive Services Task Force (USPSTF)
- Women ages 30-65 who wish to extend screening intervals may use Pap/HPV co-test every five years
Centers for Disease Control and Prevention (CDC)
- Triage for women 21 and older with ASC-US cytology. HPV/Pap co-testing in women 30+ years of age
[tabby title=”HPV Vaccines”]
American Congress of Obstetricians and Gynecologists (ACOG)
- ACOG endorses ACIP recommendations for HPV vaccination in girls and young women: routine for ages 11-12 with catch-up for ages 13-26
U.S. Preventive Services Task Force (USPSTF)
- No population-specific guidance
Centers for Disease Control and Prevention (CDC)
- ACIP recommendations for HPV vaccination in girls and young women: routine for ages 11-12 with catch-up for ages 13-26. Routine use for males ages 11-12 with catch-up for ages 13-21.
[tabbyending]